Page 20 - Gates-AnnualReport-2014

GATES BIOMANUFACTURING FACILITY
Gates Center Executive Director Patrick Gaines checks out the Gates Biomanufacturing Facility’s new bioreactor, which will enable the production of protein-based biologics for early phase clinical trials.
In the 2013 Annual Report, we described the Gates Center’s planning and early implementation of the Gates Biomanufacturing Facility, a new core facility designed to manufacture FDA-approved cellular therapies and protein-
based biologics for early-phase clinical trials. Among other efforts, the Gates Center obtained philanthropic gifts totaling $4.3 million from eight donors to cover a budgeted renovation and construction amount of $4.26 million. Further, the
Gates Frontiers Fund and one other donor provided a total of $4.1 million to cover equipment purchases for the facility.
On November 10, 2014, we hosted over 70 guests from the Anschutz Medical Community and greater Denver/Aurora community for an evening of Cellular Cocktails: an inside look at the future of stem-cell therapies and regenerative medicine. By the end of 2014, the facility was beginning to take shape with about 60% of the initial renovation having been completed.
20 Gates Center for Regenerative Medicine